Core Viewpoint - Hainan Yangpu Junhe Pharmaceutical Co., Ltd. was fined a total of 424,207.36 yuan for commercial bribery, which included the confiscation of illegal gains amounting to 224,207.36 yuan and a fine of 200,000 yuan, due to its actions of providing benefits to medical institution staff in the drug sales business [2][4]. Summary by Relevant Sections Administrative Penalty - The penalty was issued by the Danzhou Market Supervision Administration on July 1, 2025, under the administrative penalty decision number Danzhou Supervision Penalty (2025) No. 70 [3]. - The total amount of the penalty includes 224,207.36 yuan in confiscated illegal gains and a fine of 200,000 yuan, totaling 424,207.36 yuan [3]. Violations and Legal Basis - The company violated Article 7 of the Anti-Unfair Competition Law of the People's Republic of China, specifically regarding commercial bribery [3][4]. - The investigation revealed that from 2016 to 2021, the company engaged in bribery to secure drug sales opportunities with the Lingao County People's Hospital [4]. Specific Bribery Incidents - In the second half of 2019, the then-shareholder and general manager of the company, Shi Moujun, gifted 10,000 yuan in cash to the then-deputy director of Lingao County People's Hospital, Xie Mouliang [4]. - From September 2020 to June 2021, the business manager Liang Mou bribed Xie Mouliang with a total of 22,000 yuan in six installments, which facilitated drug procurement processes, involving total drug sales revenue exceeding 6.94 million yuan [4]. Related Cases and Industry Context - The former deputy director of Lingao County People's Hospital, Xie Mouliang, was also investigated and removed from office for serious violations related to accepting bribes in drug procurement and project contracting [4]. - The company, established in 2019 with a registered capital of 20 million yuan, has faced administrative penalties previously, including the revocation of the drug business license of its affiliated company in June 2024 [4]. Industry Trends and Regulatory Actions - The pharmaceutical industry has seen a rise in commercial bribery cases, prompting regulatory bodies to enhance governance through special rectification and credit punishment measures [5]. - The implementation of the medical insurance drug traceability code system starting July 1, 2025, aims to reduce gray areas in drug circulation from a technical perspective [5]. - Experts emphasize that such cases undermine fair market competition and may affect drug quality and medical safety, necessitating legal deterrence and institutional innovation for long-term governance [5][6].